Refine your search
Collections
Journals
Year
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z All
Dutta, Alok K.
- Degraded Products of Stem Bromelain Destabilize Aggregates of β-Amyloid Peptides Involved in Alzheimer’s Disease
Abstract Views :207 |
PDF Views:64
Authors
Debratna Mukherjee
1,
Payel Bhattacharjee
1,
Reema Bhattacharya
1,
Alok K. Dutta
1,
Debasish Bhattacharyya
1
Affiliations
1 Division of Structural Biology and Bioinformatics, CSIR-Indian Institute of Chemical Biology 4, Raja S.C. Mallick Road, Jadavpur, Kolkata 700 032, IN
1 Division of Structural Biology and Bioinformatics, CSIR-Indian Institute of Chemical Biology 4, Raja S.C. Mallick Road, Jadavpur, Kolkata 700 032, IN
Source
Current Science, Vol 115, No 11 (2018), Pagination: 2133-2141Abstract
Deposition of fibrils originating from monomeric β- amyloid (Aβ) peptide in brain cells is responsible for progressive neuronal damages in Alzheimer’s disease. Peptides from bromelain, a cysteine protease from Ananas comosus (pineapple), were generated after digestion with proteases under conditions similar to human gastrointestinal tract. These peptides not only inhibit the growth of Aβ-amyloid aggregates, but also irreversibly destabilize the preformed aggregates. Gel filtration followed by mass spectrometric analysis identified a pool of peptides of <700 Da in the digest. Probable composition of the peptides interacting with Aβ-peptide was predicted from homology alignment between Aβ-peptide and bromelain using bioinformatics tools. Corresponding synthetic peptides can also destabilize the preformed aggregates as observed from thioflavin T assay, transmission electron microscopy and atomic force microscopy. Aβ aggregates that were preincubated with the bromelain-derived peptides did not exert appreciable toxicity on human neuroblastoma cells (SH-SY5Y) cultured in vitro.Keywords
Alzheimer’s Disease, Aβ Peptide, Disaggregation, Stem Bromelain.Full Text
References
- Kopito, R. R., Aggresomes, inclusion bodies and protein aggregation. Trends Cell Biol., 2000, 10, 524–530.
- Tiraboschi, P., Hansen, L. A., Thal, L. J. and Corey-Bloom, J., The importance of neuritic plaques and tangles to the development and evolution of AD. Neurology, 2004, 62, 1984–1989.
- Mathis, C. A., Lopresti, B. J. and Klunk, W. E., Impact of amyloid imaging on drug development in Alzheimer’s disease. Nucl. Med. Biol., 2007, 34, 809–822.
- Kelly, G. S., Bromelain: a literature review and discussion of its therapeutic applications. Altern. Med. Rev., 1996, 1, 243– 257.
- Rowan, A. D., Buttle, D. J. and Barrett, A. J., The cysteine proteinases of the pineapple plant. Biochem. J., 1990, 266, 869–875.
- Kumakura, S., Yamashita, M. and Tsurufuji, S., Effect of bromelain on kaoline-induced inflammation in rats. Eur. J. Pharmacol., 1988, 150, 295–301.
- Maurer, H. R., Bromelain: biochemistry, pharmacology and medical use. Cell. Mol. Life Sci., 2001, 58, 1234–1245.
- Pirotta, F. and de Giuli-Morghen, C., Bromelain: antiinflammatory and serum fibronolytic activity after oral administration in the rat. Drugs Exp. Clin. Res., 1978, 4, 1–20.
- Das, S. and Bhattacharyya, D., Bromelain from pineapple: its stability and therapeutic potential. In Tropical Fruits: from Cultivation to Consumption and Health Benefits, Pineapple (eds Bogson, C. S. and Todorov, S. D.), Nova Science Publishers, Hauppauge, NY, USA, 2017, pp. 43–100.
- Dutta, S. and Bhattacharyya, D., Enzymatic, antimicrobial and toxicity studies of the aqueous extract of Ananus comosus (pineapple) crown leaf. J. Ethnopharmacol., 2013, 150, 451–457.
- Kim, M. J., Chae, S. S., Koh, Y. H., Lee, S. K. and Jo, S. A., Glutamate carboxypeptidase II: an amyloid peptide-degrading enzyme with physiological function in the brain. FASEB J., 2010, 24, 4491–4502.
- Wolfe, M. S., γ-Secretase inhibitors and modulators for Alzheimer’s disease. J. Neurochem., 2012, 120, 89–98.
- Badman, M. K., Pryce, R. A., Charge, S. B., Morris, F. and Clark, A., Fibrillar islet amyloid polypeptide (amylin) is internalized by macrophages but resists proteolytic degradation. Cell Tissue Res., 1998, 291, 285–294.
- Mueller-Steiner, S. et al., Antiamyloidogenic and neuroprotective functions of cathepsin B: implications for Alzheimer’s disease. Neuron, 2006, 51, 703–714.
- Sun, B. et al., Cystatin C-cathepsin B axis regulates amyloid beta levels and associated neuronal deficits in an animal model of Alzheimer’s disease. J. Neuron, 2008, 60, 247–257.
- De Strooper, B., Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. Physiol. Rev., 2010, 90, 465–494.
- Hasanbasic, S., Jahic, A., Karahmet, E., Sejranic, A. and Prnjavorac, B., The role of cysteine proteases in Alzheimer disease. Mater. Sociomed., 2016, 28, 235–238.
- Mukherjee, D., Multimeric proteins: its adaptation and regulation of biological activities. Ph D thesis, Jadavpur University, Kolkata, India, 2012.
- Cheeseman, C. I. and O’Neill, D., Isolation of intestinal brushborder membranes. Curr. Protoc. Cell Biol., 2006, 30, 3.21.1– 3.21.10.
- Bhattacharya, R., Fruit and stem bromelain from pineapple (Ananas comosus): stabilization and biochemical characterization of the enzymes. Ph D thesis, Jadavpur University, Kolkata, India, 2009.
- Sarath, G., Motte, R. S. D. L. and Wagner, F. W., Protease assay methods. In Proteolytic Enzymes: A Practical Approach (eds Beynon, R. J. and Bond, J. S.), IRL Press, Oxford University Press, Oxford, UK, 1996, pp. 25–55.
- Soto, C., Sigurdsson, E. M., Morelli, L., Kumar, R. A., Castano, E. M. and Frangione, B., β-Sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer’s therapy. Nature Med., 1998, 4, 822–826.
- Kuipers, B. J. H. and Gruppen, H., Prediction of molar extinction coefficients of proteins and peptides using UV absorption of the constituent amino acids at 214 nm to enable quantitative reverse phase high-performance liquid chromatography–mass spectrometry analysis. J. Agric. Food Chem., 2007, 55, 5445–5451.
- Shearman, M. S., Hawtin, S. R. and Tailor, V. J., The intracellular component of cellular 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction is specifically inhibited by β-amyloid peptides. J. Neurochem., 1995, 65, 218–227.
- Caughey, B. and Lansbury, P. T., Protofibrils, pores, fibrils, and neurodegeneration: separating the responsible protein aggregates from the innocent bystanders. Annu. Rev. Neurosci., 2003, 26, 267–298.
- Chimon, S., Shaibat, M. A., Jones, C. R., Calero, D. C., Aizezi, B. and Ishii, Y., Evidence of fibril-like β-sheet structures in a neurotoxic amyloid intermediate of Alzheimer’s β-amyloid. Nature Struct. Mol. Biol., 2007, 14, 1157–1164.
- Hoshi, M., Sato, M., Matsumoto, S., Noguchi, A., Yasutake, K., Yoshida, N. and Sato, K., Spherical aggregates of β-amyloid (amylospheroid) show high neurotoxicity and activate tau protein kinase I/glycogen synthase kinase-3β. Proc. Natl. Acad. Sci. USA, 2003, 100, 6370–6375.
- Lambert, M. P. et al., Diffusible, nonfibrillar ligands derived from Aβ1–42 are potent central nervous system neurotoxins. Proc. Natl. Acad. Sci. USA, 1998, 95, 6448–6453.
- Banks, W. A., Characteristics of compounds that cross the blood– brain barrier. BMC Neurol., 2009, 9, S1–S3.
- Hamley, I. W., Peptide fibrillization. Angew Chem. Int. Ed., 2007, 46, 8128–8147.
- Attali, R. S. et al., Complete phenotypic recovery of an Alzheimer’s disease model by a quinine–tryptophan hybrid aggregation inhibitor. PLoS ONE, 2010, 5, 1–15.
- Crone, C., The blood-brain barrier – facts and questions. In Ion Homeostasis of the Brain (eds Siesjo, B. and Sorensen, S.), Munksgaard, Copenhagen, Denmark, 1971, pp. 52–62.
- Witt, K. A. and Davis, T. P., CNS drug delivery: opioid peptides and the blood–brain barrier. AAPS J., 2006, E76–88; http://www.aapsj.org
- Kim, S., Nollen, E. A., Kitagawa, K., Bindokas, V. P. and Morimoto, R. I., Polyglutamine protein aggregates are dynamic. Nature Cell Biol., 2002, 4, 826–831.
- Lecerf, J. M. et al., Human single-chain Fv intrabodies counteract in situ Huntington aggregation in cellular models of Huntington’s disease. Proc. Natl. Acad. Sci. USA, 2001, 98, 4764–4769.
- Yang, F. et al., Curcumin inhibits formation of amyloid beta oligomers and fibrils, binds plaques, and reduces amyloid in vivo. J. Biol. Chem., 2005, 280, 5892–5901.
- Karuppagounder, S. S., Pinto, T., Xu, H., Chen, H. L., Beal, M. F. and Gibson, G. E., Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer’s disease. Neurochem. Int., 2009, 54, 111–118.
- Yamada, K., Tanaka, T., Han, D., Senzaki, K., Kameyama, T. and Nabeshima, T., Protective effects of idebenone and alphatocopherol on beta-amyloid-(1-42)-induced learning and memory deficits in rats: implication of oxidative stress in beta-amyloidinduced neurotoxicity in vivo. Eur. J. Neurosci., 1999, 11, 83–90.
- Cao, C. et al., Caffeine suppresses amyloid-β levels in plasma and brain of Alzheimer’s disease transgenic mice. J. Alzheimers Dis., 2009, 17, 681–697.
- Das, S. and Bhattacharyya, D., Destabilization of human insulin fibrils by peptides of bromelain derived from Ananas comosus (pineapple). J. Cell. Biochem., 2017, 118, 4881–4896.
- Bhattacharjee, P. and Bhattacharyya, D., Factor V activator from Daboia russelli russelli venom destabilizes β-amyloid aggregate, the hallmark of Alzheimer disease. J. Biol. Chem., 2013, 288, 30559–30570.